Clinical Trial

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the effect of olezarsen (formerly known as AKCEA-APOCIII-LRx) on the percent change in fasting triglycerides (TG) from baseline.
Protocol Amendment History 32 amendments
This ClinicalTrials.gov record has been amended 32 times since 2021-11-11; most recent amendment 2025-12-05.
Status change: Recruiting → Active, Not Recruiting 2023-11-17
Status change: Not Yet Recruiting → Recruiting 2022-01-12
Trial Details
NCT Number NCT05130450
Lead Sponsor Ionis Pharmaceuticals, Inc.
Conditions Familial Chylomicronemia Syndrome
Enrollment 60 participants
Start Date 2021-11-18
Primary Completion 2028-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2025-12-12